BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1187 related articles for article (PubMed ID: 10768243)

  • 1. Patients with dyspepsia benefit from eradication of Helicobacter pylori if other organic causes for dyspepsia were carefully ruled out.
    Bojarski C; Epple HJ; Kirstein FW; Fromm M; Bisson S; Riecken EO; Schulzke JD
    Z Gastroenterol; 2000 Mar; 38(3):211-9. PubMed ID: 10768243
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Helicobacter pylori and different topographic types of gastritis: treatment response after successful eradication therapy in functional dyspepsia.
    Koskenpato J; Färkkilä M; Sipponen P
    Scand J Gastroenterol; 2002 Jul; 37(7):778-84. PubMed ID: 12190090
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Omeprazole/amoxicillin versus triple therapy for Helicobacter pylori in duodenal ulcer disease: two-year follow-up of a prospective randomized study.
    Labenz J; Stolte M; Peitz U; Tillenburg B; Köhl H; Becker T; Börsch G
    Z Gastroenterol; 1995 Oct; 33(10):590-3. PubMed ID: 7502551
    [TBL] [Abstract][Full Text] [Related]  

  • 4. One-day quadruple therapy compared with 7-day triple therapy for Helicobacter pylori infection.
    Lara LF; Cisneros G; Gurney M; Van Ness M; Jarjoura D; Moauro B; Polen A; Rutecki G; Whittier F
    Arch Intern Med; 2003 Sep; 163(17):2079-84. PubMed ID: 14504122
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Long-term course of reflux symptoms following Helicobacter pylori eradication].
    Peitz U; Raps S; Plein K; Leodolter A; Hotz Dagger J; Malfertheiner P
    Dtsch Med Wochenschr; 2004 Mar; 129(13):671-5. PubMed ID: 15026962
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of screening for Helicobacter pylori in patients with duodenal ulceration in the primary health care setting.
    Rosengren H; Polson RJ
    Br J Gen Pract; 1996 Mar; 46(404):177-9. PubMed ID: 8731626
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Symptomatic benefit 1-3 years after H. pylori eradication in ulcer patients: impact of gastroesophageal reflux disease.
    McColl KE; Dickson A; El-Nujumi A; El-Omar E; Kelman A
    Am J Gastroenterol; 2000 Jan; 95(1):101-5. PubMed ID: 10638566
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The impact of primary antibiotic resistance on the efficacy of ranitidine bismuth citrate- vs. omeprazole-based one-week triple therapies in H. pylori eradication--a randomised controlled trial.
    Bago J; Halle ZB; Strinić D; Kućisec N; Jandrić D; Bevanda M; Tomić M; Bilić A
    Wien Klin Wochenschr; 2002 Jun; 114(12):448-53. PubMed ID: 12422579
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dual versus triple therapy: comparison of five antibiotic regimens for eradication of Helicobacter pylori in a prospective, randomized study.
    Kirstein FW; Epple HJ; Bojarski C; Victor L; Fromm M; Riecken EO; Schulzke JD
    Z Gastroenterol; 1998 Sep; 36(9):803-9. PubMed ID: 9795409
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacological effects of metronidazole+tetracycline+bismuth subcitrate versus omeprazole+amoxycillin+bismuth subcitrate in Helicobacter pylori-related gastritis and peptic ulcer disease.
    Park KN; Hahm JS; Kim HJ
    Eur J Gastroenterol Hepatol; 1994 Dec; 6 Suppl 1():S103-7. PubMed ID: 7735924
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lack of effect of treating Helicobacter pylori infection in patients with nonulcer dyspepsia. Omeprazole plus Clarithromycin and Amoxicillin Effect One Year after Treatment (OCAY) Study Group.
    Blum AL; Talley NJ; O'Moráin C; van Zanten SV; Labenz J; Stolte M; Louw JA; Stubberöd A; Theodórs A; Sundin M; Bolling-Sternevald E; Junghard O
    N Engl J Med; 1998 Dec; 339(26):1875-81. PubMed ID: 9862942
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of Helicobacter pylori virulence factor and genotypes in non-ulcer dyspepsia.
    Tan HJ; Rizal AM; Rosmadi MY; Goh KL
    J Gastroenterol Hepatol; 2006 Jan; 21(1 Pt 1):110-5. PubMed ID: 16706821
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lack of benefit of treating Helicobacter pylori infection in patients with functional dyspepsia. Randomized one-year follow-up study.
    Gisbert JP; Cruzado AI; Garcia-Gravalos R; Pajares JM
    Hepatogastroenterology; 2004; 51(55):303-8. PubMed ID: 15011890
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Eradication of Helicobacter pylori in peptic ulcer and chronic gastritis. A randomized clinical trial].
    Rodríguez Hernández H; Sánchez Anguiano LF; Quiñones E
    Rev Gastroenterol Mex; 1998; 63(1):21-7. PubMed ID: 10068745
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Comparison of the efficacy of omeprazole/bismuth subcitrate or triple therapy in Helicobacter pylori gastritis. A prospective controlled study].
    Bertschinger P; Brunner J; Flury R; Lammer F; Jost R; Häcki WH
    Schweiz Med Wochenschr; 1992 Sep; 122(39):1446-51. PubMed ID: 1411403
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bismuth subsalicylate instead of metronidazole with lansoprazole and clarithromycin for Helicobacter pylori infection: a randomized trial.
    Chey WD; Fisher L; Elta GH; Barnett JL; Nostrant T; DelValle J; Hasler WL; Scheiman JM
    Am J Gastroenterol; 1997 Sep; 92(9):1483-6. PubMed ID: 9317068
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Absence of symptomatic benefit of lansoprazole, clarithromycin, and amoxicillin triple therapy in eradication of Helicobacter pylori positive, functional (nonulcer) dyspepsia.
    Veldhuyzen van Zanten S; Fedorak RN; Lambert J; Cohen L; Vanjaka A
    Am J Gastroenterol; 2003 Sep; 98(9):1963-9. PubMed ID: 14499772
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Helicobacter pylori eradication and standardized 3-month omeprazole therapy in functional dyspepsia.
    Koskenpato J; Farkkilä M; Sipponen P
    Am J Gastroenterol; 2001 Oct; 96(10):2866-72. PubMed ID: 11693319
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevalence of H. pylori-infection in family members of H. pylori positive and its influence on the reinfection rate after successful eradication therapy: a two-year follow-up.
    Knippig C; Arand F; Leodolter A; Nilius M; Bayerdörffer E; Klein U; Malfertheiner P
    Z Gastroenterol; 2002 Jun; 40(6):383-7. PubMed ID: 12055660
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [New ultrashort scheme for helicobacter pylori infection eradication using tetracyline, furazolidone and colloidal bismuth subcitrate in dyspeptic patients with or without peptic ulceration in the National Hospital Cayetano Heredia].
    Araujo Castillo R; Pinto Valdivia JL; Ramírez D; Cok García J; Bussalleu Rivera A
    Rev Gastroenterol Peru; 2005; 25(1):23-41. PubMed ID: 15818420
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 60.